MSD's Prevymis Gains 100-Day CMV Prophylaxis Extension in China

MSD has received approval from China's National Medical Products Administration (NMPA) to extend the use of Prevymis (letermovir) for cytomegalovirus (CMV) prevention to 200 days post-hematopoietic stem cell transplant (HSCT) in adults at risk of late-onset infection. The oral and intravenous formulations of this non-nucleoside CMV inhibitor were previously limited to 100-day prophylaxis. Clinical data showed 12% of patients developed clinically significant CMV infections after stopping Prevymis at 100 days, prompting this label expansion.

Prevymis remains the only approved CMV prophylactic for HSCT recipients aged 6 months and above in China. The drug is listed in China's National Reimbursement Drug Directory for CMV-seropositive adult HSCT patients. MSD China President Kyle Tattle highlighted its role in personalised CMV management. The approval follows MSD's recent paediatric expansion for Prevymis in China.

PharmCube's NextBiopharm® database lists 67 CMV innovative drug programs currently active and developed by 72 companies, including a number of Big Pharmas. Click here to request a free trial for NextBiopharm®.

Daily News
MediLink Files B7-H3 ADC as First Phase III-Proven Candidate Globally
2026-07-21
Vincentage Files First Domestic Oral GLP-1 Agonist in China
2026-07-21
BriSTAR's Allogeneic STAR-T Product YTS109 Clears US FDA IND for AIHA
2026-07-20
MSD's Oral PCSK9 Inhibitor Nodded for Hypercholesterolaemia in US
2026-07-20
BI Celebrates Strong H1'26 Growth Driven by Human Pharma Expansion
2026-07-17
Latest Report
2026 TOP-25 Drug Targets
Details